EUVIMEDEUVIMED entdecken
Open Access

Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors

Cecile Maxime Van De Leur iD, Leon Mg Moons, Frank Vleggaar, Paul Didden

Endoscopy International Open · 19.03.2026 · 14 (CP)

DOI: 10.1055/a-2798-2041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy International Open, erschienen am 19.03.2026. Verfasst von Cecile Maxime Van De Leur und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, Netherlands. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and study aims Effective strategies to prevent delayed bleeding (DB) following endoscopic mucosal resection (EMR) for large superficial non-ampullary duodenal tumors (SNADTs) remain limited. Octreotide exerts pharmacological effects that may influence hemostasis and thereby reduce bleeding risk. This exploratory study aimed to evaluate the association between postprocedural octreotide use and DB after duodenal EMR for large SNADTs. Patients and methods This single-center, exploratory, retrospective study included all hot EMRs for large SNADTs ≥ 10 mm (2015–2024). Routine post-procedural intravenous octreotide (50 μg/h) was introduced in 2022, administered immediately post-EMR at 50 μg/hour during overnight observation. DB was defined as clinically significant bleeding within 30 days requiring prolonged hospitalization, readmission, or intervention.

Results

A total of 107 SNADTs (median diameter 25 mm; interquartile range 15–40) were resected, including 33 treated with octreotide. Overall, DB occurred in 20% of patients (21/107), including 24% (18/74) in the control group and 9% (3/33) in the octreotide group. In logistic regression adjusting for lesion size and propensity score, octreotide showed a non-significant trend toward reduced DB overall (odds ratio [OR] 0.34; 95% confidence interval [CI] 0.08–1.17; P = 0.11). In the subgroup of lesions ≥ 30 mm, octreotide use was associated with a significantly lower odds of DB (OR 0.21; 95% CI 0.039–0.89; P = 0.045), whereas this association was not observed in smaller lesions.

Conclusions

In this exploratory study, postprocedural intravenous octreotide appeared to be associated with a lower occurrence of DB after EMR for large SNADTs (≥ 30 mm). Larger, prospective studies are warranted to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

Endoscopic resection (ESD, EMRc, ...)Endoscopy Lower GI TractEndoscopy Upper GI TractPerformance and complicationsPolyps / adenomas / ...Quality and logistical aspects

Autor:innen und Institutionen

  • Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, Netherlands.

ORCID-Profile: Cecile Maxime Van De Leur

Zitieren

APA

Van De Leur, C. M., Moons, L. M., Vleggaar, F., & Didden, P. (2026). Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors. Endoscopy International Open, 14(CP). https://doi.org/10.1055/a-2798-2041

Vancouver

Van De Leur CM, Moons LM, Vleggaar F, Didden P. Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors. Endoscopy International Open. 2026;14(CP). doi:10.1055/a-2798-2041

BibTeX
@article{VanDeLeur2026,
  author = {Van De Leur, Cecile Maxime and Moons, Leon Mg and Vleggaar, Frank and Didden, Paul},
  title = {Octreotide for prevention of delayed bleeding after endoscopic mucosal resection for large superficial non-ampullary duodenal tumors},
  journal = {Endoscopy International Open},
  year = {2026},
  volume = {14},
  number = {CP},
  doi = {10.1055/a-2798-2041}
}
Kostenlos starten →